Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Donor T-cell-derived GM-CSF drives alloantigen presentation by dendritic cells in the gastrointestinal tract.

Gartlan KH, Koyama M, Lineburg KE, Chang K, Ensbey KS, Kuns RD, Henden AS, Samson LD, Clouston AD, Lopez AF, MacDonald KPA, Hill GR.

Blood Adv. 2019 Oct 8;3(19):2859-2865. doi: 10.1182/bloodadvances.2019000053.

2.

Anti-βc mAb CSL311 inhibits human nasal polyp pathophysiology in a humanized mouse xenograft model.

Yip KH, Wilson NJ, Pant H, Brown CL, Busfield S, Ng M, Alhamdoosh M, Woodman N, Schembri M, Tumes DJ, Vairo G, Lopez AF, Nash AD, Wilson MJ, Grimbaldeston MA, Owczarek CM.

Allergy. 2019 Sep 10. doi: 10.1111/all.14041. [Epub ahead of print] No abstract available.

PMID:
31505024
3.

Author Correction: EPO does not promote interaction between the erythropoietin and beta-common receptors.

Cheung Tung Shing KS, Broughton SE, Nero TL, Gillinder K, Ilsley MD, Ramshaw H, Lopez AF, Griffin MDW, Parker MW, Perkins AC, Dhagat U.

Sci Rep. 2019 May 21;9(1):7851. doi: 10.1038/s41598-019-43988-9.

4.

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis.

Tvorogov D, Thomas D, Liau NPD, Dottore M, Barry EF, Lathi M, Kan WL, Hercus TR, Stomski F, Hughes TP, Tergaonkar V, Parker MW, Ross DM, Majeti R, Babon JJ, Lopez AF.

Sci Adv. 2018 Nov 28;4(11):eaat3834. doi: 10.1126/sciadv.aat3834. eCollection 2018 Nov.

5.

Systematic review of drug bioavailability following gastrointestinal surgery.

Santamaría MM, Villafranca JJA, Abilés J, López AF, Rodas LV, Goitia BT, Navarro PU.

Eur J Clin Pharmacol. 2018 Dec;74(12):1531-1545. doi: 10.1007/s00228-018-2539-9. Epub 2018 Aug 22.

PMID:
30136101
6.

EPO does not promote interaction between the erythropoietin and beta-common receptors.

Cheung Tung Shing KS, Broughton SE, Nero TL, Gillinder K, Ilsley MD, Ramshaw H, Lopez AF, Griffin MDW, Parker MW, Perkins AC, Dhagat U.

Sci Rep. 2018 Aug 20;8(1):12457. doi: 10.1038/s41598-018-29865-x. Erratum in: Sci Rep. 2019 May 21;9(1):7851.

7.

The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities.

Dhagat U, Hercus TR, Broughton SE, Nero TL, Cheung Tung Shing KS, Barry EF, Thomson CA, Bryson S, Pai EF, McClure BJ, Schrader JW, Lopez AF, Parker MW.

MAbs. 2018 Oct;10(7):1018-1029. doi: 10.1080/19420862.2018.1494107. Epub 2018 Sep 12.

8.

NLS-Cholic Acid Conjugation to IL-5Rα-Specific Antibody Improves Cellular Accumulation and In Vivo Tumor-Targeting Properties in a Bladder Cancer Model.

Paquette M, Beaudoin S, Tremblay MA, Jean S, Lopez AF, Lecomte R, Guérin B, Bentourkia M, Sabbagh R, Leyton JV.

Bioconjug Chem. 2018 Apr 18;29(4):1352-1363. doi: 10.1021/acs.bioconjchem.8b00077. Epub 2018 Mar 1.

PMID:
29433309
9.

A dual role for the N-terminal domain of the IL-3 receptor in cell signalling.

Broughton SE, Hercus TR, Nero TL, Kan WL, Barry EF, Dottore M, Cheung Tung Shing KS, Morton CJ, Dhagat U, Hardy MP, Wilson NJ, Downton MT, Schieber C, Hughes TP, Lopez AF, Parker MW.

Nat Commun. 2018 Jan 26;9(1):386. doi: 10.1038/s41467-017-02633-7.

10.

High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression.

Wittwer NL, Brumatti G, Marchant C, Sandow JJ, Pudney MK, Dottore M, D'Andrea RJ, Lopez AF, Ekert PG, Ramshaw HS.

Blood Adv. 2017 Jun 20;1(15):1067-1079. doi: 10.1182/bloodadvances.2016002931. eCollection 2017 Jun 27.

11.

Targeting IL-5Rα with antibody-conjugates reveals a strategy for imaging and therapy for invasive bladder cancer.

Paquette M, Vilera-Perez LG, Beaudoin S, Ekindi-Ndongo N, Boudreaut PL, Bonin MA, Battista MC, Bentourkia M, Lopez AF, Lecomte R, Marsault E, Guérin B, Sabbagh R, Leyton JV.

Oncoimmunology. 2017 May 19;6(10):e1331195. doi: 10.1080/2162402X.2017.1331195. eCollection 2017.

12.

Role of salt bridges in the dimer interface of 14-3-3ζ in dimer dynamics, N-terminal α-helical order, and molecular chaperone activity.

Woodcock JM, Goodwin KL, Sandow JJ, Coolen C, Perugini MA, Webb AI, Pitson SM, Lopez AF, Carver JA.

J Biol Chem. 2018 Jan 5;293(1):89-99. doi: 10.1074/jbc.M117.801019. Epub 2017 Nov 6.

13.

Corrigendum: 14-3-3ζ regulates the mitochondrial respiratory reserve linked to platelet phosphatidylserine exposure and procoagulant function.

Schoenwaelder SM, Darbousset R, Cranmer SL, Ramshaw HS, Orive SL, Sturgeon S, Yuan Y, Yao Y, Krycer JR, Woodcock J, Maclean J, Pitson S, Zheng Z, Henstridge DC, van der Wal D, Gardiner EE, Berndt MC, Andrews RK, James DE, Lopez AF, Jackson SP.

Nat Commun. 2017 Aug 30;8:16125. doi: 10.1038/ncomms16125.

14.

The transcriptional program, functional heterogeneity, and clinical targeting of mast cells.

Cildir G, Pant H, Lopez AF, Tergaonkar V.

J Exp Med. 2017 Sep 4;214(9):2491-2506. doi: 10.1084/jem.20170910. Epub 2017 Aug 15. Review.

15.

Role of the β Common (βc) Family of Cytokines in Health and Disease.

Hercus TR, Kan WLT, Broughton SE, Tvorogov D, Ramshaw HS, Sandow JJ, Nero TL, Dhagat U, Thompson EJ, Shing KSCT, McKenzie DR, Wilson NJ, Owczarek CM, Vairo G, Nash AD, Tergaonkar V, Hughes T, Ekert PG, Samuel MS, Bonder CS, Grimbaldeston MA, Parker MW, Lopez AF.

Cold Spring Harb Perspect Biol. 2018 Jun 1;10(6). pii: a028514. doi: 10.1101/cshperspect.a028514. Review.

PMID:
28716883
16.

Risk factors and outcomes of organ-space surgical site infections after elective colon and rectal surgery.

Gomila A, Carratalà J, Camprubí D, Shaw E, Badia JM, Cruz A, Aguilar F, Nicolás C, Marrón A, Mora L, Perez R, Martin L, Vázquez R, Lopez AF, Limón E, Gudiol F, Pujol M; VINCat colon surgery group.

Antimicrob Resist Infect Control. 2017 Apr 21;6:40. doi: 10.1186/s13756-017-0198-8. eCollection 2017.

17.

Proteome Analysis of Drosophila Mutants Identifies a Regulatory Role for 14-3-3ε in Metabolic Pathways.

Ng YS, Sorvina A, Bader CA, Weiland F, Lopez AF, Hoffmann P, Shandala T, Brooks DA.

J Proteome Res. 2017 May 5;16(5):1976-1987. doi: 10.1021/acs.jproteome.6b01032. Epub 2017 Apr 13.

PMID:
28365999
18.

Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study".

Hughes A, Clarson J, Gargett T, Yu W, Brown MP, Lopez AF, Hughes TP, Yong AS.

Leuk Res. 2017 Apr;55:55-57. doi: 10.1016/j.leukres.2017.01.009. Epub 2017 Jan 9. No abstract available.

PMID:
28129558
19.

GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells in vitro.

Gargett T, Christo SN, Hercus TR, Abbas N, Singhal N, Lopez AF, Brown MP.

Clin Transl Immunology. 2016 Dec 23;5(12):e119. doi: 10.1038/cti.2016.80. eCollection 2016 Dec.

20.

Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.

Powell JA, Lewis AC, Zhu W, Toubia J, Pitman MR, Wallington-Beddoe CT, Moretti PA, Iarossi D, Samaraweera SE, Cummings N, Ramshaw HS, Thomas D, Wei AH, Lopez AF, D'Andrea RJ, Lewis ID, Pitson SM.

Blood. 2017 Feb 9;129(6):771-782. doi: 10.1182/blood-2016-06-720433. Epub 2016 Dec 12.

PMID:
27956387
21.

The Nedd4-2/Ndfip1 axis is a negative regulator of IgE-mediated mast cell activation.

Yip KH, Kolesnikoff N, Hauschild N, Biggs L, Lopez AF, Galli SJ, Kumar S, Grimbaldeston MA.

Nat Commun. 2016 Oct 27;7:13198. doi: 10.1038/ncomms13198.

22.

14-3-3ζ regulates the mitochondrial respiratory reserve linked to platelet phosphatidylserine exposure and procoagulant function.

Schoenwaelder SM, Darbousset R, Cranmer SL, Ramshaw HS, Orive SL, Sturgeon S, Yuan Y, Yao Y, Krycer JR, Woodcock J, Maclean J, Pitson S, Zheng Z, Henstridge DC, van der Wal D, Gardiner EE, Berndt MC, Andrews RK, James DE, Lopez AF, Jackson SP.

Nat Commun. 2016 Sep 27;7:12862. doi: 10.1038/ncomms12862. Erratum in: Nat Commun. 2017 Aug 30;8:16125.

23.

Conformational Changes in the GM-CSF Receptor Suggest a Molecular Mechanism for Affinity Conversion and Receptor Signaling.

Broughton SE, Hercus TR, Nero TL, Dottore M, McClure BJ, Dhagat U, Taing H, Gorman MA, King-Scott J, Lopez AF, Parker MW.

Structure. 2016 Aug 2;24(8):1271-1281. doi: 10.1016/j.str.2016.05.017. Epub 2016 Jul 7.

24.

A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis.

Ebert LM, Tan LY, Johan MZ, Min KK, Cockshell MP, Parham KA, Betterman KL, Szeto P, Boyle S, Silva L, Peng A, Zhang Y, Ruszkiewicz A, Zannettino AC, Gronthos S, Koblar S, Harvey NL, Lopez AF, Shackleton M, Bonder CS.

Angiogenesis. 2016 Oct;19(4):463-86. doi: 10.1007/s10456-016-9520-y. Epub 2016 Jun 23.

25.

Ywhaz/14-3-3ζ Deletion Improves Glucose Tolerance Through a GLP-1-Dependent Mechanism.

Lim GE, Piske M, Lulo JE, Ramshaw HS, Lopez AF, Johnson JD.

Endocrinology. 2016 Jul;157(7):2649-59. doi: 10.1210/en.2016-1016. Epub 2016 May 11.

PMID:
27167773
26.

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, Busfield SJ, Vairo G, Fuller K, Erber WN, Sadras T, Grose R, Yeung DT, Lopez AF, Hiwase DK, Hughes TP, White DL.

Leukemia. 2016 Jun;30(6):1263-72. doi: 10.1038/leu.2016.34. Epub 2016 Feb 22.

PMID:
26898188
27.

A Negative Regulatory Mechanism Involving 14-3-3ζ Limits Signaling Downstream of ROCK to Regulate Tissue Stiffness in Epidermal Homeostasis.

Kular J, Scheer KG, Pyne NT, Allam AH, Pollard AN, Magenau A, Wright RL, Kolesnikoff N, Moretti PA, Wullkopf L, Stomski FC, Cowin AJ, Woodcock JM, Grimbaldeston MA, Pitson SM, Timpson P, Ramshaw HS, Lopez AF, Samuel MS.

Dev Cell. 2015 Dec 21;35(6):759-74. doi: 10.1016/j.devcel.2015.11.026.

28.

CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors.

Panousis C, Dhagat U, Edwards KM, Rayzman V, Hardy MP, Braley H, Gauvreau GM, Hercus TR, Smith S, Sehmi R, McMillan L, Dottore M, McClure BJ, Fabri LJ, Vairo G, Lopez AF, Parker MW, Nash AD, Wilson NJ, Wilson MJ, Owczarek CM.

MAbs. 2016;8(3):436-53. doi: 10.1080/19420862.2015.1119352. Epub 2015 Dec 14.

29.

Jak2V617F driven myeloproliferative neoplasm occurs independently of interleukin-3 receptor beta common signaling.

Vu T, Austin R, Kuhn CP, Bruedigam C, Song A, Guignes S, Jacquelin S, Ramshaw HS, Hill GR, Lopez AF, Lane SW.

Haematologica. 2016 Mar;101(3):e77-80. doi: 10.3324/haematol.2015.136705. Epub 2015 Nov 20. No abstract available.

30.

14-3-3ζ coordinates adipogenesis of visceral fat.

Lim GE, Albrecht T, Piske M, Sarai K, Lee JTC, Ramshaw HS, Sinha S, Guthridge MA, Acker-Palmer A, Lopez AF, Clee SM, Nislow C, Johnson JD.

Nat Commun. 2015 Jul 29;6:7671. doi: 10.1038/ncomms8671.

31.

14-3-3ζ deficient mice in the BALB/c background display behavioural and anatomical defects associated with neurodevelopmental disorders.

Xu X, Jaehne EJ, Greenberg Z, McCarthy P, Saleh E, Parish CL, Camera D, Heng J, Haas M, Baune BT, Ratnayake U, van den Buuse M, Lopez AF, Ramshaw HS, Schwarz Q.

Sci Rep. 2015 Jul 24;5:12434. doi: 10.1038/srep12434.

32.

Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.

Lee EM, Yee D, Busfield SJ, McManus JF, Cummings N, Vairo G, Wei A, Ramshaw HS, Powell JA, Lopez AF, Lewis ID, McCall MN, Lock RB.

Haematologica. 2015 Jul;100(7):914-26. doi: 10.3324/haematol.2014.113092.

33.

The βc receptor family - Structural insights and their functional implications.

Broughton SE, Nero TL, Dhagat U, Kan WL, Hercus TR, Tvorogov D, Lopez AF, Parker MW.

Cytokine. 2015 Aug;74(2):247-58. doi: 10.1016/j.cyto.2015.02.005. Epub 2015 May 14. Review.

PMID:
25982846
34.

Destabilisation of dimeric 14-3-3 proteins as a novel approach to anti-cancer therapeutics.

Woodcock JM, Coolen C, Goodwin KL, Baek DJ, Bittman R, Samuel MS, Pitson SM, Lopez AF.

Oncotarget. 2015 Jun 10;6(16):14522-36.

35.

Interleukin-3 greatly expands non-adherent endothelial forming cells with pro-angiogenic properties.

Moldenhauer LM, Cockshell MP, Frost L, Parham KA, Tvorogov D, Tan LY, Ebert LM, Tooley K, Worthley S, Lopez AF, Bonder CS.

Stem Cell Res. 2015 May;14(3):380-95. doi: 10.1016/j.scr.2015.04.002. Epub 2015 Apr 9.

36.

Unexpected mechanisms of action for a cytokine receptor-blocking antibody.

Hercus TR, Broughton SE, Hardy MP, Nero TL, Wilson NJ, Parker MW, Lopez AF.

Mol Cell Oncol. 2014 Dec 31;1(4):e969129. doi: 10.4161/23288604.2014.969129. eCollection 2014 Oct-Dec.

37.

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.

He SZ, Busfield S, Ritchie DS, Hertzberg MS, Durrant S, Lewis ID, Marlton P, McLachlan AJ, Kerridge I, Bradstock KF, Kennedy G, Boyd AW, Yeadon TM, Lopez AF, Ramshaw HS, Iland H, Bamford S, Barnden M, DeWitte M, Basser R, Roberts AW.

Leuk Lymphoma. 2015 May;56(5):1406-15. doi: 10.3109/10428194.2014.956316. Epub 2014 Nov 20.

PMID:
25248882
38.

14-3-3ε and ζ regulate neurogenesis and differentiation of neuronal progenitor cells in the developing brain.

Toyo-oka K, Wachi T, Hunt RF, Baraban SC, Taya S, Ramshaw H, Kaibuchi K, Schwarz QP, Lopez AF, Wynshaw-Boris A.

J Neurosci. 2014 Sep 3;34(36):12168-81. doi: 10.1523/JNEUROSCI.2513-13.2014.

39.

Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody.

Broughton SE, Hercus TR, Hardy MP, McClure BJ, Nero TL, Dottore M, Huynh H, Braley H, Barry EF, Kan WL, Dhagat U, Scotney P, Hartman D, Busfield SJ, Owczarek CM, Nash AD, Wilson NJ, Parker MW, Lopez AF.

Cell Rep. 2014 Jul 24;8(2):410-9. doi: 10.1016/j.celrep.2014.06.038. Epub 2014 Jul 17.

40.

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.

Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Ghosh S, Braley H, Panousis C, Roberts AW, He SZ, Thomas D, Fabri L, Vairo G, Lock RB, Lopez AF, Nash AD.

Leukemia. 2014 Nov;28(11):2213-21. doi: 10.1038/leu.2014.128. Epub 2014 Apr 7.

PMID:
24705479
41.

Crystallization and preliminary X-ray diffraction analysis of the interleukin-3 alpha receptor bound to the Fab fragment of antibody CSL362.

Broughton SE, Hercus TR, Nero TL, Dhagat U, Owczarek CM, Hardy MP, Fabri LJ, Scotney PD, Nash AD, Wilson NJ, Lopez AF, Parker MW.

Acta Crystallogr F Struct Biol Commun. 2014 Mar;70(Pt 3):358-61. doi: 10.1107/S2053230X14002593. Epub 2014 Feb 19.

42.

Interleukin-3-mediated regulation of β-catenin in myeloid transformation and acute myeloid leukemia.

Sadras T, Perugini M, Kok CH, Iarossi DG, Heatley SL, Brumatti G, Samuel MS, To LB, Lewis ID, Lopez AF, Ekert PG, Ramshaw HS, D'Andrea RJ.

J Leukoc Biol. 2014 Jul;96(1):83-91. doi: 10.1189/jlb.2AB1013-559R. Epub 2014 Mar 5.

PMID:
24598054
43.

Mechanisms of vitamin D₃ metabolite repression of IgE-dependent mast cell activation.

Yip KH, Kolesnikoff N, Yu C, Hauschild N, Taing H, Biggs L, Goltzman D, Gregory PA, Anderson PH, Samuel MS, Galli SJ, Lopez AF, Grimbaldeston MA.

J Allergy Clin Immunol. 2014 May;133(5):1356-64, 1364.e1-14. doi: 10.1016/j.jaci.2013.11.030. Epub 2014 Jan 22.

44.

IL-4 Derived from Non-T Cells Induces Basophil- and IL-3-independent Th2 Immune Responses.

Kim S, Karasuyama H, Lopez AF, Ouyang W, Li X, Le Gros G, Min B.

Immune Netw. 2013 Dec;13(6):249-56. doi: 10.4110/in.2013.13.6.249. Epub 2013 Dec 20.

45.

Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells.

Nievergall E, Ramshaw HS, Yong AS, Biondo M, Busfield SJ, Vairo G, Lopez AF, Hughes TP, White DL, Hiwase DK.

Blood. 2014 Feb 20;123(8):1218-28. doi: 10.1182/blood-2012-12-475194. Epub 2013 Dec 20.

PMID:
24363400
46.

High yield production of a soluble human interleukin-3 variant from E. coli with wild-type bioactivity and improved radiolabeling properties.

Hercus TR, Barry EF, Dottore M, McClure BJ, Webb AI, Lopez AF, Young IG, Murphy JM.

PLoS One. 2013 Aug 26;8(8):e74376. doi: 10.1371/journal.pone.0074376. eCollection 2013.

47.

Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.

Thomas D, Powell JA, Vergez F, Segal DH, Nguyen NY, Baker A, Teh TC, Barry EF, Sarry JE, Lee EM, Nero TL, Jabbour AM, Pomilio G, Green BD, Manenti S, Glaser SP, Parker MW, Lopez AF, Ekert PG, Lock RB, Huang DC, Nilsson SK, Récher C, Wei AH, Guthridge MA.

Blood. 2013 Aug 1;122(5):738-48. doi: 10.1182/blood-2012-08-447441. Epub 2013 Jun 17.

PMID:
23775716
48.

Signalling by the βc family of cytokines.

Hercus TR, Dhagat U, Kan WL, Broughton SE, Nero TL, Perugini M, Sandow JJ, D'Andrea RJ, Ekert PG, Hughes T, Parker MW, Lopez AF.

Cytokine Growth Factor Rev. 2013 Jun;24(3):189-201. doi: 10.1016/j.cytogfr.2013.03.002. Epub 2013 Mar 25. Review.

PMID:
23535386
49.

Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival.

Thomas D, Powell JA, Green BD, Barry EF, Ma Y, Woodcock J, Fitter S, Zannettino AC, Pitson SM, Hughes TP, Lopez AF, Shepherd PR, Wei AH, Ekert PG, Guthridge MA.

PLoS Biol. 2013;11(3):e1001515. doi: 10.1371/journal.pbio.1001515. Epub 2013 Mar 19.

50.

Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state.

Lim YY, Wright JA, Attema JL, Gregory PA, Bert AG, Smith E, Thomas D, Lopez AF, Drew PA, Khew-Goodall Y, Goodall GJ.

J Cell Sci. 2013 May 15;126(Pt 10):2256-66. doi: 10.1242/jcs.122275. Epub 2013 Mar 22.

Supplemental Content

Loading ...
Support Center